Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 7.10 |
---|---|
High | 7.35 |
Low | 7.10 |
Bid | 7.00 |
Offer | 7.25 |
Previous close | 6.95 |
Average volume | 33.44 |
---|---|
Shares outstanding | 76.38m |
Free float | 49.35m |
P/E (TTM) | 403.06 |
Market cap | 582.80m USD |
EPS (TTM) | 0.0189 USD |
Data delayed at least 15 minutes, as of Nov 22 2024 09:17 GMT.
More ▼
Press releases
- ChromaDex’s Patented Nicotinamide Riboside (NR) Ingredient, Niagen®, Featured as the Hero Ingredient in Longevity.Technology’s Inaugural Longevity Supplement
- ChromaDex's Pharmaceutical-Grade Niagen® IV Now Accessible at over 200 Restore Hyper Wellness Clinics Nationwide
- ChromaDex Corporation Reports Third Quarter 2024 Financial Results
- ChromaDex to Report Third Quarter 2024 Financial Results on Thursday, October 31, 2024
- ChromaDex to Participate in the 17th Annual LD Micro Main Event
- Yasmeen Nkrumah-Elie, Ph.D., Global Director of External Research at ChromaDex, Honored with the Trailblazing Woman Award by Radicle Science and Council for Responsible Nutrition (CRN)
- ChromaDex to Participate in a Fireside Chat at the Lytham Partners Fall 2024 Investor Conference
- ChromaDex Appoints Ozan Pamir as Chief Financial Officer
- ChromaDex Announces Expansion of Pharmaceutical-Grade Niagen® IV and Injection Offerings to Additional Leading Wellness Clinics
- ChromaDex Celebrates 25 Years of Innovation and Pioneering NAD+ Research for Healthy Aging Solutions
More ▼